This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 18.18% and 12.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Guardant Health (GH) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health (GH) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 15.79% and 9.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Merus (MRUS) delivered earnings and revenue surprises of -6.58% and 23.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health (GH) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Stock Market News for May 13, 2024
by Zacks Equity Research
U.S. stocks closed mixed on Friday as investors awaited the April Consumer Price Index report, which is influential in shaping the Federal Reserve's interest rate policies, alongside assessing quarterly earnings.
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 36.11% and 11.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 150% and 13.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -69.89% and 2.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?